Evidence map›Paper›PMID 38565305›Full record

Trial reportRespiratory care2024

Direct Health Care Costs Associated With a Multicomponent COPD Exacerbation Intervention.

Louise Rose, Laura Istanboulian, Shaghayegh Rezaie, Ian Fraser

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Respiratory care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Louise RoseFlorence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, United Kingdom louise.rose@kcl.ac.uk.
Laura IstanboulianMedicine Health Service, Michael Garron Hospital, Toronto, Ontario, Canada; and Daphne Cockwell School of Nursing, Toronto Metropolitan University, Toronto, Ontario, Canada.
Shaghayegh RezaieDepartment of Family and Community Medicine, Michael Garron Hospital, Toronto, Ontario, Canada.
Ian FraserMedicine Health Service, Michael Garron Hospital, Toronto, Ontario, Canada; and Division of Respirology, Michael Garron Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Toronto East General Hospital · CAKing's College London · GBSt. Michael's Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHealth care costs attributed to COPD have been estimated at $4.7 trillion globally in the next 30 years. With the global burden of COPD rising, identification of interventions that might lead to health care cost savings is an imperative. Although many studies report the effect of COPD self-management interventions on subject outcomes and health care utilization, few data describe their effect on health care costs.

methodsUsing data linkage and established case-costing methods with provincial Canadian health databases, we established public health care costs (acute and community) for 12 months following randomization for the 462 participants enrolled in our randomized controlled trial of the Program of Integrated Care for Patients with COPD and Multiple Comorbidities.

resultsTotal median (interquartile range) in-hospital costs in the 12 months follow-up for all (intervention and control) 462 trial participants were CAD $4,769 ($417-16,834) (equivalent to US $3,566 [$312-12,588]). Total costs incurred in the community were higher at CAD $8,011 ($4,749-13,831) (equivalent to US $5,990 [$3,551-10,342]). Controlling for sex, income quintile, Johns Hopkins Aggregated Diagnosis Groups score, and living in an urban locality, we found lower community health care costs but no differences in acute care costs for participants receiving our multicomponent COPD exacerbation prevention management intervention compared to usual care.

conclusionsControlling for important confounders, we found lower public community health care costs but no difference in acute health care costs with our multicomponent COPD exacerbation prevention management intervention compared to usual care. Community health care costs were almost double those incurred compared to acute health care costs. Given this finding, although most COPD exacerbation management interventions generally focus on reducing the use of acute care, interventions that enable health care cost savings in the community require further exploration.

Indexed as

Health Care CostsPulmonary Disease, Chronic ObstructiveAgedCanadaDisease ProgressionFemaleHospital CostsHospitalizationHumansMaleMiddle AgedCOPDdata linkagehealth administrative databaseshealth care costsself-management

Identifiers

PMID38565305
PMCPMC11298227
OpenAlexW4393408017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.